A novel strategy for soft tissue sarcoma lattice radiotherapy: integrating X-ray andγ-ray technologies to optimize dose delivery Authors: Zhongfei Wang, Qinghui Yun, Te Zhang, Xiaohuan Sun, Wei Wang, Jie Duan, Liting Chen, Yue Gao, Ziqi An, Changhao Liu, Jian Zang, Pengfei Zhang, Lina Zhao Published: 2026 ABSTRACT AbstractBackgroundThe TaiChi radiotherapy platform is an innovative system integrating linear accelerator (LINAC) and Gamma Knife technologies, approved by both NMPA and FDA. This hybrid design enables bimodal (X-ray and γ-ray) radiation delivery, offering enhanced flexibility for treatment planning and dose delivery. This study quantitatively evaluates its dosimetric performance for lattice radiotherapy (LRT) in soft tissue sarcoma (STS), specifically comparing its dose escalation potential and normal tissue sparing to conventional C-arm LINAC.MethodsA dosimetric analysis was conducted on 10 STS cases. The treatment combined LRT (15 Gy single fraction to spherical vertices within the Gross tumor volume (GTV)) with conventionally fractionated external beam radiotherapy (50 Gy/25F to the planning target volume (PTV)). TaiChi utilized its dual-modality capability, employing γ-ray focusing for vertex dose escalation and optimizing the LINAC for conventional coverage. Plans were compared on high-dose vertex coverage, dose fall-off, and organ-at-risk (OAR) sparing.ResultsTaiChi demonstrated superior dosimetric performance across all evaluated parameters. For vertex coverage, TaiChi achieved significantly higher D0.5cc (25.15 ± 0.39 Gy vs. 18.90 ± 0.44 Gy, p < 0.0001) and Dmean (18.87 ± 0.46 Gy vs. 16.66 ± 0.85 Gy, p < 0.0001). Dose gradient analysis revealed steeper fall-off with TaiChi, evidenced by higher GTV D10/D90 values (5.93 ± 0.84 vs. 3.40 ± 0.92, p < 0.0001) and reduced margin doses (3.95 ± 0.48 Gy vs. 4.87 ± 0.41 Gy, p < 0.0001). Importantly, these improvements were achieved while maintaining or reducing OAR exposure, with statistically reductions in maximum doses to nerves and bones (p < 0.05).ConclusionThe TaiChi platform’s innovative integration of LINAC and Gamma Knife technologies provides distinct dosimetric advantages for STS LRT, enabling superior dose escalation to high-dose vertex regions while maintaining steep dose gradients and effective normal tissue sparing. These capabilities position TaiChi as a promising platform for advancing LRT applications.Clinical trial numberNot applicable.Keywords: Soft tissue sarcomas, Lattice radiotherapy, X-ray/γ-ray Introduction Soft tissue sarcomas (STS) are a diverse group of malignancies characterized by considerable clinical and pathological heterogeneity, collectively accounting for less than 1% of adult cancers but approximately 15% of pediatric malignancies [1]. Diagnosis often occurs when tumors are large, with the extremities being the most common primary site. [2, 3] Clinical evidence supports the National Comprehensive Cancer Network (NCCN) recommendation for either preoperative or postoperative radiotherapy (RT) in large (> 8 cm), high-grade STS. The standard neoadjuvant external beam RT (EBRT) regimen is 50 Gy, delivered in fractions of 1.8 to 2.0 Gy [1]. The advancement of radiation therapy technologies has established intensity-modulated radiation therapy (IMRT) combined with image guidance radiotherapy (IGRT) as the preferred EBRT modality, primarily due to its superior ability to minimize toxic effects [4]. Despite their implementation being linked to reduced toxicity, IMRT combined with IGRT has not demonstrated superiority in survival or disease control outcomes [5]. GRID radiation therapy technique was originally developed by Alban Köhler in the 1950s for safe treatment of bulky tumors using kV x-ray technology [6, 7]. In the megavoltage radiotherapy era, GRID has been repurposed for palliative management of large tumors with positive outcomes, now formally termed spatially fractionated radiotherapy (SFRT) [8–15]. Emerging in 2010 as a three-dimensional extension, LATTICE radiotherapy (LRT) leverages contemporary treatment delivery systems—such as MLC-based linacs for IMRT/VMAT, robotic convergent beam systems (e.g., CyberKnife), and particle therapy units utilizing proton or carbon-ion Bragg peaks—to create high-dose vertices within tumors. This generates characteristic peak-valley dose distributions while sparing surrounding tissues [16, 17]. Owing to its superior normal tissue sparing compared to GRID, LRT represents a rational strategy for further dose escalation. The implementation of LRT is feasible through multiple platforms, including MLC-based linacs, robotic radiosurgery systems with fixed circular collimators (e.g., CyberKnife), and particle therapy units (proton/carbon ions), though each approach entails unique trade-offs in clinical application [17–19]. Dosimetric analyses of photon, proton, and carbon-ion LRT modalities revealed comparable peak-to-valley dose ratios (PVDR). Nevertheless, particle-based approaches (proton/carbon-ion) demonstrated superior organ-at-risk (OAR) sparing relative to photon techniques [19]. Gamma Knife’s status as the intracranial SRS gold standard stems from its ability to create sharp dose fall-offs at small target boundaries, sparing critical organs [20, 21]. These dosimetric characteristics—namely, steep dose gradients and critical organ sparing—may enable higher PVDR values when implementing LRT techniques. A novel TaiChi radiotherapy platform, featuring an integrated linear accelerator (LINAC), rotating gamma system, and kV imaging subsystem within a sealed O-ring gantry, has entered clinical use(NMPA: 20223050973; FDA: K210921). The platform facilitates synchronous administration of photon-based IMRT/VMAT and gamma knife-equivalent SRS, consolidating dual modalities in a single treatment ecosystem. This consolidated platform offers potential benefits for patients requiring sequential LRT followed by conventional fractionation external beam radiation therapy (cEBRT) using a sequential, rather than a simultaneous, approach. The gamma-knife component first delivers focused high-dose radiation to LRT vertices with submillimeter accuracy, followed by the linac component delivering homogeneous dose distributions to the planning target volume (PTV) with conventional fractionation. This study investigates Taichi’s dosimetric advantages in LRT for large STS, hypothesizing that it outperforms conventional VMAT in vertex dose escalation, dose gradient quality, and OAR protection. Materials and methods TaiChi radiotherapy platform Within a unified O-ring gantry, the advanced TaiChi radiotherapy platform combines three coplanar modalities sharing a common isocenter: (1) a MV X-ray based linac for external beam therapy, (2) a γ-ray based rotating gamma system, and (3) a kV X-ray imaging system (Fig. 1). Commissioning confirmed the system’s compliance with clinical standards, exhibiting excellent mechanical precision and dosimetric accuracy [22]. Equipped with a 120-leaf MLC, the linac delivers 6 MV photons with field sizes ranging from 0.5 × 0.5 cm² to 40 × 40 cm². The gamma system employs 18 Cobalt-60 sources geometrically focused at the isocenter with incident angles ranging from − 13.3° to 13.3°, and is capable of rotational arc delivery. It offers seven collimator sizes (Φ6, 9, 12, 16, 20, 25, and 35 mm) for treatment. The gamma system employs 18 Cobalt-60 sources with seven collimator sizes (Φ6, 9, 12, 16, 20, 25, and 35 mm). For imaging, a kV X-ray tube and flat-panel detector provide 2D radiographic and 3D Cone Beam Computed Tomography (CBCT) capabilities. TaiChi utilizes the dedicated RT PRO treatment planning system (TPS), featuring a preloaded Golden Beam Data model, which supports planning for both linac/MLC and gamma knife treatments, including hybrid planning with the collapsed cone convolution (CCC) dose algorithm. Clinically, gamma knife demonstrates superior efficacy for small, well-defined targets, while linac/MLC is more appropriate for large, irregular targets [23–25]. Though each modality can be used independently (linac for conventional RT, gamma system for SRS), their sequential use on the same platform enables optimized dose distributions for challenging cases by combining the sharp dose gradients of γ-ray focusing for focal boost with the conformal coverage of X-ray IMRT for irregular target volumes. This synergy, supported by previous studies in pancreatic and cervical cancers, allows for dose escalation to high-risk regions while sparing adjacent OARs [26, 27]. Assembly drawing of the TaiChi platform. The linear accelerator (LINAC), γ-ray rotating system, and kV X-ray imaging system (kV X-Ray source and kV detector) are integrated within a coplanar rotating gantry, sharing a common isocenter. Red beam: X-ray from linac; Yellow beam: focused γ-ray beam༛Pink beam: kV X-ray for imaging Patient selection, CT simulation, and target delineation Ten patients were retrospectively selected from our institution’s digital medical archives based on the following inclusion criteria: (1) histologically confirmed soft tissue sarcoma; (2) tumor located in the lower extremity; (3) large tumor size defined as maximum diameter ≥ 8 cm. All selected patients had complete imaging and treatment planning data available for analysis. Patients were immobilized using a vacuum-based fixation system to minimize intrafraction motion.Simulation was performed using the Philips Brilliance Big Bore CT scanner with a 1 mm slice thickness. Gross tumor volume (GTV) was delineated on planning CT using MRI fusion, while clinical target volume (CTV) encompassed a 1.5 cm margin from the GTV in radial direction and 4 cm in superior/inferior direction, and the CTV was uniformly expanded by 5 mm in all three dimensions to generate the PTV. Within the GTV, spherical high-dose vertices (diameter 0.9–1.5 cm) were automatically arranged using the smart radiotherapy contouring software smART Vision Pro V1.3.0 (Shenying MedTech Co., Ltd., Shenzhen, China). The software generated vertices with a center-to-center separation of 3.0–3.5 cm, ensuring they occupied 1–10% of the GTV volume (modal value 2%) and maintained an inward margin of 1–2 cm from the GTV boundary to spare normal tissues, in accordance with recommended guidelines [17]. This automated approach ensures reproducible and objective vertex placement, eliminating the subjectivity of manual delineation. Nerve and bone were delineated as organs at risk (OARs). Treatment planning The treatment consisted of two courses: (1) LRT: 15 Gy single fraction to high-dose vertices; (2) cEBRT: 50 Gy in 25 fractions (2 Gy/fx) to PTV. LRT prescription necessitates defining three dosimetric parameters: peak dose (covering ≥ 95% of cumulative volume of all high-dose vertices), PVDR (GTV D₁₀/D₉₀), and tumor peripheral dose (maximum allowable dose at tumor margin, typically ≤ 5 Gy) to mitigate normal tissue toxicity. Linac planning Clinical treatment plans were developed on a Varian iX linac (6MV) using Eclipse 13.5 TPS with VMAT optimization. For LRT delivery, six co-planar partial arcs (220°rotation) avoided contralateral leg irradiation, employing collimator angles of 45°and 315°to deliver 15 Gy in single fraction to high-dose vertices. The cEBRT phase utilized two partial VMAT arcs for conventional fractionation (50 Gy total, 2 Gy/fx) to PTV. All dose calculations employed the anisotropic analytical algorithm (AAA) at 2 mm grid resolution. Patient-specific quality assurance (QA) for LRT plans was performed using the IBA myQA SRS system with a 2%/2 mm and a 10% dose threshold criterion. TaiChi planning The TaiChi treatment plans were implemented in RTPRO TPS (OUR United Corp., China) using dual-modality optimization strategy: The Gamma knife-based LRT plan was initially optimized to cover the high-dose vertices (15 Gy/1 fx). Subsequent 6 MV linac VMAT optimization achieved PTV coverage (50 Gy/25 fx) using the same target prescription and OAR dose constraints as those applied in the conventional linac plans, based on published recommendations [28]. The RTPRO TPS allows for optimization of γ-ray LRT and linac-based cEBRT plans within a single environment, facilitating accurate cumulative dose assessment. Dose calculations employed CCC algorithm at 2 mm resolution. Patient-specific QA for LRT utilized IBA myQA SRS systems with a 2%/2 mm and a 10% dose threshold criterion. Comparison metrics Dosimetric comparisons between the clinical Linac plans and Taichi plans were made to evaluate the ability of the technique to deliver high doses to the vertices while minimizing dose to OARs and the non-LATTICE target volume within the GTV. Dose heterogeneity was quantified via the PVDR. The PVDR is traditionally defined as the ratio of peak dose to valley dose measured at a given depth along a one-dimensional dose profile in GRID therapy [29]. However, for bulky tumors treated with three-dimensional lattice radiotherapy (LRT), a single-depth PVDR value may not adequately represent the volumetric dose heterogeneity [30]. Therefore, following the recommendations of recent studies [29–31], we used the D₁₀/D₉₀ ratio—derived from the dose–volume histogram of the GTV—as a robust metric to quantify the overall three-dimensional dose gradient. D10 and D90 represent the doses covering 10% and 90% of the GTV volume, respectively. Target dose analysis included the comparison of D0.5cc (dose covering 0.5 cc volume), and mean dose (Dmean) for vertices. The dosimetric evaluation of cEBRT plans was performed using the dose conformity index (CI) and homogeneity index (HI). The CI, defined as (PTVDp/PTV)×(PTVDp/VDp)-where PTVDp is the planning target volume receiving the prescription dose and VDp is the total volume enclosed by the prescription isodose line།ranges from 0 to 1, with values closer to 1 indicating better conformity. The HI, calculated as (D2-D98)/D50 (where D2, D50, and D98 represent the doses covering 2%, 50%, and 98% of the target volume, respectively), reflects dose homogeneity, with lower values indicating a more homogeneous dose distribution within the target. The OARs evaluation encompassed Dmax and Dmean for nerve, bone. Statistical analysis employed two-tailed paired t-tests with a significance threshold of p < 0.05. Results The GTVs ranged from 208.8 to 627.4 cm³, with a mean GTV of 419.3 cm³. The number of high-dose vertices ranged from 7 to 15, and the vertices volume accounted for 1.9% to 2.8% of the GTV (mean 2.3%), which fell well within the recommended range of 1–10% cited in the literature [17]. All treatment plans met clinical dosimetric criteria. This study focuses on evaluating the comparative performance of LRT plans delivered via conventional linac versus gamma knife systems. Consequently, our analysis emphasizes the distinctions between these two LRT modalities. Representative dose distributions and dose-volume histograms (DVHs) for TaiChi and conventional linac plans are displayed in Fig. 2 (one selected case). All plans were normalized to ensure that 95% of vertex volume received the prescribed dose of 15 Gy. Comparative dosimetric parameters for targets and OARs of LRT plans are showed in Table 1; Fig. 3. The TaiChi plans demonstrated significantly enhanced dose delivery to vertices compared to conventional linac plans, with higher Dmean (18.87 ± 0.46 Gy vs. 16.66 ± 0.85 Gy, p < 0.0001) and D0.5cc(25.15 ± 0.39 Gy vs. 18.90 ± 0.44 Gy, p < 0.0001). Furthermore, The TaiChi system demonstrated significantly improved dose gradient characteristics, with higher D10/D90 values of GTV(5.93 ± 0.84 Gy vs. 3.40 ± 0.92 Gy, p < 0.0001) and lower doses of GTV margin (3.95 ± 0.48 Gy vs. 4.87 ± 0.41 Gy, p < 0.0001). The OAR dose metrics are listed in Table 1. The TaiChi plans achieved comparable or reduced OAR exposure, with statistically reductions in Dmax for nerve, bone (all p < 0.05). Taichi improved vertex dose escalation by 33% and OAR sparing by 15–35%. The Taichi’s γ-ray component enabled sharper dose gradients, reducing non-target tumor irradiation. Regarding cEBRT plans, both approaches utilize linac-based VMAT techniques. Comparative dosimetric parameters for targets and OARs of cEBRT plans are showed in Table 2; Fig. 4. No statistically significant differences were observed in either targets or OARs, consequently, the cEBRT plans are not discussed in detail in this study. Dose distributions (A)、DVH(B) and PVDR(C) for the Linac plan and TaiChi plan of a selected case. (A): Axial, sagittal, and coronal views of dose distribution for a LRT plan (left: TaiChi plan; right: Linac plan); (B): DVH comparison of the GTV (purple curves) and vertices (cyan curves) between the TaiChi plan (solid lines) and the Linac plan (dashed lines). (C): The corresponding dose profiles (PVDR) across vertices (yellow: TaiChi plan; green: Linac plan) Table 1Dosimetric comparison of target volumes between TaiChi Plans and Lianc Plans (LRT Plan)Parameters(Gy)TaiChi plansLinac plansp-valueVertices D0.5 cc25.15 ± 0.3918.90 ± 0.44< 0.0001Vertices Dmean18.87 ± 0.4616.66 ± 0.85< 0.0001Dose GTV margin3.95 ± 0.484.87 ± 0.41< 0.0001GTV D10/D905.93 ± 0.843.40 ± 0.92< 0.0001Nerve Dmax4.35 ± 2.056.11 ± 1.89< 0.0001Nerve Dmean1.18 ± 0.631.82 ± 0.70< 0.0001Bone Dmax4.79 ± 1.546.30 ± 2.030.0003Bone Dmean1.70 ± 0.681.98 ± 0.940.036 Dosimetric comparison of target volumes between TaiChi Plans and Lianc Plans (LRT Plan) Dosimetric comparison of target volumes and critical organs between TaiChi plans (blue) and linac plans (red) in LRT plans. Significance levels: * (p ≤ 0.05), *** (p ≤ 0.001), **** (p ≤ 0.0001) Table 2Dosimetric comparison of target volumes between TaiChi plans and Lianc plans (cEBRT Plan)Parameters(Gy)TaiChi plansLinac plansp-valuePTV D253.90 ± 0.6653.30 ± 0.500.334PTV D9849.39 ± 0.0849.31 ± 0.110.506PTV CI0.94 ± 0.020.95 ± 0.010.467PTV HI0.084 ± 0.0120.081 ± 0.0110.541Nerve Dmax53.6 ± 1.0353.2 ± 1.060.855Nerve Dmean20.58 ± 4.4320.82 ± 4.600.722Bone Dmax53.60 ± 1.5452.58 ± 0.590.687Bone Dmean25.30 ± 3.4425.08 ± 3.270.836 Dosimetric comparison of target volumes between TaiChi plans and Lianc plans (cEBRT Plan) Dosimetric comparison of target volumes and critical organs between TaiChi plans (blue) and linac plans (red) in cEBRT plans. Significance levels: ns (p ≥ 0.05) All LRT plans demonstrated clinically acceptable patient-specific QA results, achieving gamma-index passing rates exceeding 95% with a stringent 2%/2 mm (10% low dose threshold) criterion. Specifically, linac plans demonstrated a pass rate of 97.3% ± 1.4%, while TaiChi plans achieved 97.1% ± 1.0% via IBA myQA SRS system validation for patient-specific QA. Figure 5 demonstrates the Patient-specific QA results of a representative TaiChi LRT plan, achieving a 97.5% gamma passing rate with 2%/2 mm (10% low dose threshold) criteria using an IBA myQA SRS system. Patient-specific QA results of a representative TaiChi LRT plan using an IBA myQA SRS system. Left: plan dose distribution; Middle: measured dose distribution; Right: gamma index image with 2%/2 mm (10% low dose threshold), passing rate 97.5% Discussion In this study, we conducted a comparative analysis of the clinical dosimetry advantages offered by bimodal X-ray/γ-ray LRT for soft tissue sarcomas using the Taichi platform. To the best of our knowledge, this represents the first systematic investigation evaluating the dosimetric benefits between the innovative Taichi platform and conventional linear accelerators in STS LRT applications. The integrated design of the TaiChi platform—which combines a linac and a rotating gamma system within a single O-ring gantry—provides a distinct advantage for the sequential delivery of LRT and cEBRT. As demonstrated in our study, the TaiChi platform achieves higher dose escalation to target vertices while preserving sharp dose gradients and effectively sparing adjacent critical tissues compared to conventional linac-based delivery. SFRT encompasses multiple modalities including GRID, LATTICE, micro-beam, and mini-beam techniques [32–36]. As a recently emerged novel approach, preliminary clinical data demonstrate LRT’s favorable safety profile with no severe treatment-related toxicities reported to date. Tumor response rates mirror those observed in GRID therapy, confirming technical feasibility [37, 38]. The delivery of ablative radiation to selective tumor subvolumes achieves substantial debulking, with additional localized dose escalation (boost therapy) to viable tumor regions resulting in substantially improved tumor control rates when normal tissue dose limits are respected [39]. Maximizing peak-to-valley dose differentials remains clinically advantageous, but current photon technologies exhibit inherent limitations in achieving valley dose reduction [17]. As the first implementation of Gamma Knife in STS LRT, our study demonstrates distinct dosimetric advantages: higher PVDR(D10/D90) combined with reduced peripheral doses at GTV margins and diminished exposure to OARs. These dosimetric advantages originate from three fundamental characteristics of Taichi’s Gamma Knife technology: (1) superior penumbral sharpness inherent to gamma rays compared to X-ray modalities; (2) an intrinsic spherical dose-painting mechanism—physically congruent with spatially fractionated radiotherapy principles—that generates higher D10/D90 than MLC-based linac systems; and (3) dynamic rotational isocentric delivery enabled by hemispheric convergence of 18 Co-60 sources synchronized with continuous gantry rotation, collectively steepening target dose gradients through multiplanar focusing. Furthermore, the TaiChi platform pioneers the integration of kV X-ray and γ-ray modalities within a single unit. As established earlier, its Gamma Knife component delivers LRT to high-dose vertices (e.g., 15 Gy ×1), while the linac-based X-ray system administers cEBRT to the PTV (e.g., 2 Gy ×25), in accordance with published recommendation for LRT and standard soft tissue sarcoma radiotherapy [28]. This dual-capability design precisely aligns with the combined LRT+cEBRT dose paradigm recommended for soft tissue sarcomas—establishing TaiChi as an optimized radiotherapy platform for implementing this therapeutic strategy. This study presents several limitations. First, the modest cohort size (n = 10) and retrospective nature constrain the generalizability of clinical inferences. Prospective randomized trials incorporating larger patient populations are required to establish robust correlations between observed dosimetric benefits and clinically meaningful endpoints including progression-free survival, locoregional control, and late toxicity profiles. Second, the conventional linac plans were generated using Eclipse version 13.5, which represents a limitation as newer TPS versions may offer further optimization; future studies incorporating updated planning systems are warranted to validate the robustness of these comparative findings. Third, critical parameters for LRT vertex configuration - including optimal spatial distribution and geometric characteristics - remain to be standardized. Future studies employing computational radiomics or hypoxia-specific PET biomarkers may facilitate biologically-guided vertex positioning to target radioresistant tumor subvolumes. Conclusion The TaiChi platform’s innovative integration of LINAC and Gamma Knife technologies provides distinct dosimetric advantages for STS LRT, enabling superior dose escalation to high-dose vertex regions while maintaining steep dose gradients and effective normal tissue sparing. Physical advantages include: (1) γ-ray focusing for precise vertex dose escalation, (2) LINAC-based modulation for conventional target coverage, and (3) synergistic dose distribution optimization. These capabilities position TaiChi as a promising platform for advancing LRT applications. Further clinical validation and protocol optimization are warranted to translate these physical advantages into improved patient outcomes. Acknowledgements Not applicable. Abbreviations Linear accelerator Lattice radiotherapy Soft tissue sarcoma National Comprehensive Cancer Network Spatially fractionated radiotherapy External beamradiotherapy Intensity-modulated radiation therapy Image guidance radiotherapy Volumetric modulated arc therapy Peak-to-valley dose ratios Organ-at-risk Planning target volume Cone Beam Computed Tomography Treatment planning system Collapsed cone convolution Anisotropic analytical algorithm Gross tumor volume Clinical target volume Dose-volume histograms Conformity index Homogeneity index Author contributions Zhongfei Wang and Qinghui Yun contributed equally to this work. Zhongfei Wang, Qinghui Yun: Treatment Planning, Data Curation, Writing. Changhao Liu, Te Zhang, Xiaohuan Sun: Investigation, Treatment Planning. Wei Wang, Jie Duan, Liting Chen, Yue Gao, Ziqi An, Jian Zang, Pengfei Zhang: Data Curation, Validation. Lina Zhao: Project Administration, Funding Acquisition. All authors read and approved the final manuscript. Funding This work was supported by the Key Technologies Research and Development Program of China (Grant No. 2023YFC2413903). Data availability The datasets used and/or analyzed during the current study are available from the first author on reasonable request. Declarations Ethics approval and consent to participate This study was approved by the Ethics Committee of the First Affiliated Hospital of Air Force Medical University (approval no. KY20252211-F-1) and was conducted in accordance with the Declaration of Helsinki. The requirement for informed consent was waived by the committee due to the retrospective and anonymized nature of the study. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Zhongfei Wang and Qinghui Yun contributed equally to this work. References Associated Data Data Availability Statement The datasets used and/or analyzed during the current study are available from the first author on reasonable request.